StreetAlpha.app
Home › Stocks › ELTX

Elicio Therapeutics, Inc. (ELTX)

Healthcare
$1.43
▼ −3.38%
LAST CLOSE · NOV 17

Elicio Therapeutics is a Boston biotech developing lymph node targeted cancer immunotherapies, mainly for cancers with mutant KRAS. It last closed at $1.43 on Nov 17, down 3.38% on the day. The average 12-month price target from 2 analysts is $14.50 (+914.0% from the last close), with a high of $21.00 and a low of $8.00.

AI Auto Pilots
Is ELTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$35.7M
EPS (diluted)
−$1.81
Valuation
Market cap
$40.5M
28.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$30.9M
At Sep 30
Debt
$9.6M
At Sep 30
Shareholder equity
$18.9M
Shares outstanding
28.3M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$54.6M−$54.6MFY2021FY2022: −$28.2M−$28.2MFY2022FY2023: −$35.2M−$35.2MFY2023FY2024: −$51.9M−$51.9MFY2024FY2025: −$39.6M−$39.6MFY2025

From ELTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ELTX in the past 90 days, not enough for a consensus
Average 12-month target
$14.50
▲ 914.0% upside

Based on 2 analysts who set a price target on ELTX in the past 90 days. The average target is $14.50, with a high of $21.00 and a low of $8.00, compared with the last close of $1.43.

Low $8.00Avg $14.50High $21.00
Blue marker: last close $1.43
Highest target$21.00
Average target$14.50
Lowest target$8.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 10Buy$23 → $21
B. Riley SecuritiesTarget lowered
Sep 24Buy$27 → $8
HC Wainwright & Co.Reiterated
Aug 18Buy$23
Ladenburg ThalmannAssumed coverage
Jun 18Buy$12
HC Wainwright & Co.Maintained
Jun 15Buy$23
DateFirmActionRatingPrice target
Nov 10HC Wainwright & Co.Target loweredBuy$23 → $21
Sep 24B. Riley SecuritiesTarget loweredBuy$27 → $8
Aug 18HC Wainwright & Co.ReiteratedBuy$23
Jun 18Ladenburg ThalmannAssumed coverageBuy$12
Jun 15HC Wainwright & Co.MaintainedBuy$23
Loading…

Technical Analysis

ELTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 24% below its 50 day average. It is 347% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $1.35, and the nearest resistance the Pivot at $1.45.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 12.3%/day
Key levels
$16.0052 week high+1018.9%
$6.39200 day average+346.9%
$2.43100 day average+69.9%
$1.7750 day average+23.8%
$1.77Swing high (Nov 10)+23.8%
$1.6420 day average+14.7%
$1.52Pivot R1+6.3%
$1.45Pivot+1.4%
$1.43Last close
$1.35Pivot S1−5.6%
$1.2552 week low−12.6%
$1.25Swing low (Nov 6)−12.6%
Indicators
RSI (14)37.36Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic34.4Middle of its rangeNeutral
ADX (14)28.0Trending down
Williams %R-71.9Oversold below −80, overbought above −20Neutral
CCI (20)-116.6Oversold below −100, overbought above 100Oversold
Rate of change−5.9%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ELTX

What happened before

See how ELTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ELTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ELTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ELTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

ELTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲59 buying vs 12 selling
  • ▲Held by funds +12.0 pts
  • ▲Funds holding +32
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8149+65.3%
In funds' top 1010–
Held by funds25.9%13.9%+12.0 pts
New / increased37 / 2224 / 14+55.3%
Reduced / sold out7 / 52 / 23−52.0%
Put/call ratio17.770.61+2804.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELTX is in one of them and how their past ELTX trades turned out.

ELTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELTX in an article yet. Here's the latest on the wider market.

About Elicio Therapeutics

Elicio Therapeutics is a biotechnology company based in Boston, Massachusetts, that is developing cancer immunotherapies. Its lead candidate, ELI-002 7P, is in clinical trials for pancreatic cancer and is also being studied in colorectal cancer. The company's treatments are designed to deliver immune signals to lymph nodes to generate T cell responses against tumors. Its target patients are those with cancers driven by mutant KRAS, a gene mutation found in many solid tumors.

Headquarters
Boston, MA